Novartis AG (NVSN) — Cash Flow-to-Debt Ratio
Novartis AG (NVSN) has a Cash Flow-to-Debt Ratio of 0.05x as of March 2026, meaning its operating cash flow of MX$3.68 Billion could theoretically repay 0% of its total liabilities (MX$79.61 Billion) in one year. See Novartis AG free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Novartis AG Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Novartis AG across 12 annual periods. Also explore Novartis AG annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Novartis AG (2014–2025)
Year-by-year debt coverage analysis for Novartis AG. For market capitalisation and broader financial context, see NVSN company net worth.
| Year | CF-to-Debt Ratio | Operating CF (MXN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | MX$19.14 Billion | MX$64.40 Billion | ▼ -1.9% |
| 2024 | 0.30x | MX$17.62 Billion | MX$58.12 Billion | ▲ +0.6% |
| 2023 | 0.30x | MX$16.02 Billion | MX$53.20 Billion | ▲ +22.8% |
| 2022 | 0.25x | MX$14.24 Billion | MX$58.03 Billion | ▲ +4.1% |
| 2021 | 0.24x | MX$15.07 Billion | MX$63.97 Billion | ▲ +30.1% |
| 2020 | 0.18x | MX$13.65 Billion | MX$75.39 Billion | ▼ -16.5% |
| 2019 | 0.22x | MX$13.62 Billion | MX$62.82 Billion | ▲ +1.6% |
| 2018 | 0.21x | MX$14.27 Billion | MX$66.87 Billion | ▼ -0.5% |
| 2017 | 0.21x | MX$12.62 Billion | MX$58.85 Billion | ▲ +3.2% |
| 2016 | 0.21x | MX$11.47 Billion | MX$55.23 Billion | ▼ -4.9% |
| 2015 | 0.22x | MX$11.90 Billion | MX$54.43 Billion | ▼ -14.2% |
| 2014 | 0.25x | MX$13.90 Billion | MX$54.54 Billion | — |